Updated on 9 June 2016
Several Asian companies have been increasing their focus on biosimilars, terming it a long term prospect. Although currently small and focused on few diseases, the biosimilars opportunity is all set to grow, thanks to the unprecedented patent cliff and rising healthcare costs. Biosimilars are an affordable option for Asia's growing healthcare needs and this has offered a clear potential for players in emerging Asian countries to set up operations and leverage this lucrative opportunity.
One such interesting company is a start up in Taiwan - JHL Biotech, which aims to build a biotech industry in China. Founded in 2012, by two former Genentech colleagues, JHL Biotech has already received the EU approval to perform clinical trials for its biosimilar rituximab and is planning to file an (Investigational New Drug) IND for its upcoming orphan drug biosimilar by the end of this year.
JHL is the first Chinese company to file a clinical trial for biosimilar in the Europe. The company has two factories, one for clinical manufacturing and development in Hsinchu in Taiwan, and one for commercial manufacturing and process development in Wuhan. JHL is also the first to use GE Healthcare's KuBio factory design, that can be built and dispatched anywhere in the world in just 18 months.
In an exclusive interview with BioSpectrum Asia Magazine, Mr Racho Jordanov, President and CEO, JHL Biotech.
Please check below for excerpts: